- VolitionRx ( NYSE: VNRX ) received a further $1.5M non-dilutive funding from Namur Invest Capital Risk in Belgium.
- The funding is unsecured, bears interest at a rate of 6% per year and is repayable over four years with a maturity date of July 31, 2026.
- Namur Invest's award will fund an early access program for Volition's Nu.Q product portfolio at key sites across the EU, U.K., and U.S.
- Namur Invest's loan is the latest grant from agencies within the Walloon Region, amounting to $14M+ in non-dilutive funding since 2016.
For further details see:
VolitionRx secures $1.5M in non-dilutive funding